Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc. News
Jun 11, 2025 - prnewswire.com
Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
Dec 26, 2024 - prnewswire.com
Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing
Northwest Biotherapeutics, Inc. Quantitative Score
About Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Northwest Biotherapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Northwest Biotherapeutics, Inc. Financials
Table Compare
Compare NWBO metrics with: | |||
|---|---|---|---|
Earnings & Growth | NWBO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | NWBO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | NWBO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | NWBO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Northwest Biotherapeutics, Inc. Income
Northwest Biotherapeutics, Inc. Balance Sheet
Northwest Biotherapeutics, Inc. Cash Flow
Northwest Biotherapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Northwest Biotherapeutics, Inc. Executives
| Name | Role |
|---|---|
| Ms. Linda F. Powers J.D. | Chairperson, Chief Executive Officer, President, Chief Financial Officer & Chief Accounting Officer |
| Mr. Leslie J. Goldman | Senior Vice President & General Counsel |
| Dr. Marnix L. Bosch M.B.A., Ph.D. | Chief Technical Officer |
| Dr. Alton L. Boynton Ph.D. | Founder, Chief Scientific Officer, Secretary & Director |
| Mr. David Innes | Vice President of Investor Relations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Linda F. Powers J.D. | Chairperson, Chief Executive Officer, President, Chief Financial Officer & Chief Accounting Officer | Female | 1956 | 925K |
| Mr. Leslie J. Goldman | Senior Vice President & General Counsel | Male | 1945 | 725K |
| Dr. Marnix L. Bosch M.B.A., Ph.D. | Chief Technical Officer | 1959 | 453.6K | |
| Dr. Alton L. Boynton Ph.D. | Founder, Chief Scientific Officer, Secretary & Director | 1945 | -- | |
| Mr. David Innes | Vice President of Investor Relations | Male | -- |
Northwest Biotherapeutics, Inc. Insider Trades
| Date | 29 Aug |
| Name | BOYNTON ALTON L |
| Role | CHIEF SCIENTIFIC OFFICER |
| Transaction | Disposed |
| Type | G-Gift |
| Shares | 1000000 |
| Date | 9 Aug |
| Name | BOSCH MARNIX L |
| Role | CHIEF TECHNICAL OFFICER |
| Transaction | Disposed |
| Type | G-Gift |
| Shares | 3000000 |
| Date | 8 Aug |
| Name | BOYNTON ALTON L |
| Role | CHIEF SCIENTIFIC OFFICER |
| Transaction | Disposed |
| Type | G-Gift |
| Shares | 1000000 |
| Date | 26 Jul |
| Name | MALIK NAVID |
| Role | Director |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 657895 |
| Date | 16 Nov |
| Name | MALIK NAVID |
| Role | Director |
| Transaction | Acquired |
| Type | S-Sale |
| Shares | 125000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 29 Aug | BOYNTON ALTON L | CHIEF SCIENTIFIC OFFICER | Disposed | G-Gift | 1000000 |
| 9 Aug | BOSCH MARNIX L | CHIEF TECHNICAL OFFICER | Disposed | G-Gift | 3000000 |
| 8 Aug | BOYNTON ALTON L | CHIEF SCIENTIFIC OFFICER | Disposed | G-Gift | 1000000 |
| 26 Jul | MALIK NAVID | Director | Disposed | S-Sale | 657895 |
| 16 Nov | MALIK NAVID | Director | Acquired | S-Sale | 125000 |